AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01544894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: 60 mg/d for one year
Study NCT01544894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strontium ranelate
Description: 2 g/d, for one year
Study NCT02205255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
Study NCT02205255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02414594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-APO(a)-LRx
Description: Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
Study NCT02414594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study NCT04131036 — intervention group
Intervention type: OTHER
Intervention: assessment of joint health and bone density
Description: We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
Study NCT01558999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High concentration SI-614
Description: 1 drop in each eye 4 times a day
Study NCT01558999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low concentration SI-614
Description: 1 drop in each eye 4 times a day
Study NCT01558999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye 4 times a day
Study NCT00299676 — intervention group
Intervention type: DRUG
Intervention: Galantamine (Reminyl)
Description: Use of Reminyl according to approved NZ data sheet
Study NCT01623609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
Study NCT01623609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
Study NCT03905577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Action Observation training
Study NCT03046394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-SACH
Description: Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
Study NCT03905577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: Motor imagery protocol
Study NCT03905577 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Action observation
Description: Placebo Action Observation
Study NCT03405922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 40 mL Saline 0.9%
Description: Injection of 40 mL 0.9% saline
Study NCT03405922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mL Ropivacain 0.5%
Description: Ropivacaine Hcl 0.5% Injection 40 mL
Study NCT03046394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-DER
Description: Dynamic Motion by Otto Bock, advertised for activity category 2-3
Study NCT03046394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A-DER
Description: Triton by Otto Bock, advertised for activity category 3-4
Study NCT00000250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O
Description: Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
Study NCT00527332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
Study NCT00527332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
Study NCT00527332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronbromid
Description: 0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
Study NCT00527332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 5 mg is given IV (intravenously) before end of surgery
Study NCT04309058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D drops
Description: Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
Study NCT04427449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD44v6-specific CAR gene-engineered T cells
Description: 4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10\^6 cells/kg body weight
Study NCT02147769 — intervention group
Intervention type: DEVICE
Intervention: NIRS monitoring
Description: All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
Study NCT00865319 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)
Description: one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
Study NCT00865319 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18 F fluorodeoxyglucose
Description: single injection of 18F FDG (range 10-20mCi)
Study NCT03597061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Start to Feeding
Description: The intervention provides parent education and skills training on a responsive feeding approach to introduction of healthy foods in infancy. Session content is manualized and administered by interventionists with expertise in child development and behavioral strategies for managing child eating behaviors under the supervision of a licensed clinical child psychologist and pediatric occupational therapist. Sessions are conducted individually with participants and primary caregivers and include educational content, handouts and instructions, modeling of skills by the interventionist, caregiver practicing of skills in session, establishment of behavioral goals, and problem solving barriers to implementation of treatment content. Content will include topics such as allowing infants' own hunger and satiety cues to guide the feeding experience, introducing healthy foods, parental attunement to infant satiety cues, and promoting infants' own self-feeding.
Study NCT02160145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan (OPC-41061)
Description: Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
Study NCT02160145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
Study NCT00566254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: 8mg/kg per day for approximately 24 weeks.
Study NCT00566254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02635997 — intervention group
Intervention type: DRUG
Intervention: antiresorptive therapy
Study NCT02992535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulse Light Energy delivery (IPL)
Study NCT03731078 — intervention group
Intervention type: OTHER
Intervention: CBT Informed physical therapy Intervention
Description: The 12 physical therapy sessions delivered in Massachusetts General Hospital outpatient physical therapy sites sessions include:1) evaluation and education; 2) strategy identification and goal setting; 3) functional strengthening part one; 4) functional strengthening part two; 5) pre-gait activities with distraction; 6) gait training with distraction and use of strategies; 7) minimizing tremor with use of strategies; 8) higher level balance training; 9) functional reintegration part one; 10) functional reintegration part two; 11) identification of strategies to limit recurrence; 12) education for relapse prevention.Patients will also be given and asked to complete the self-guided CBT workbookL Overcoming Functional Neurological Symptoms: A Five Area Approach. They will be asked to complete the first two chapters over the first 4 weeks and the remaining 8 chapters over the following 8 weeks.
Study NCT00000250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O
Description: Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
Study NCT04570488 — intervention group
Intervention type: OTHER
Intervention: EPIC risk score display
Description: Display of risk score/ colored flag in Epic patient list column
Study NCT03869307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
Study NCT03869307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
Study NCT02633592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HRARM
Description: Patients and healthy volunteers are investigated in the seated and lying position during HRAM
Study NCT00603798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod cream
Description: 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
Study NCT00603798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
Study NCT03048604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genio(TM) bilateral hypoglossal nerve stimulation system
Description: Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
Study NCT01412385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous (Human), 20%
Description: Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
Study NCT01412385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10%
Description: Intravenous infusion (regulated via a pump)
Study NCT01412385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)
Description: Subcutaneous infusion (regulated via a pump)
Study NCT02343705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Latella Knee Implant System
Study NCT02133807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific Lp(a) apheresis
Description: Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol
Study NCT02103413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-BD
Description: When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
Study NCT02103413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTBD
Description: PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
Study NCT03147989 — intervention group
Intervention type: DRUG
Intervention: MultiHance
Description: gadolinium contrast agent
Study NCT04546542 — intervention group
Intervention type: OTHER
Intervention: Parallel Assignment
Description: We will evaluate 75 patients with pSS (Consenso Americano-europeu de 2002 / EULAR/ACR Classification Criteria, 2016) of both sexes at baseline and 6-months
Study NCT01124981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haemocomplettan® P
Description: Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
Study NCT01124981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human albumin (Placebo)
Description: Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
Study NCT04320108 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: Extracorporeal shockwave therapy 6 times during 2 weeks
Study NCT04320108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: Extracorporeal shockwave therapy 6 times during 2 weeks
Study NCT03809910 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Reference MTB
Description: Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
Study NCT03809910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference PTB
Description: Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
Study NCT03809910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype PTB (Gum line mode)
Description: Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff.
Study NCT05656456 — intervention group
Intervention type: OTHER
Intervention: Y-BOCS or FAS online survey, interview
Description: Y-BOCS or FAS and online survey will be administered interview will be conducted
Study NCT03884478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
Study NCT03884478 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized Normative Feedback
Description: Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
Study NCT02486939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-0214
Description: Open label
Study NCT00164021 — intervention group
Intervention type: PROCEDURE
Intervention: Physiotherapy, exercise, percutaneous gastrostomy feeds
Study NCT00164021 — intervention group
Intervention type: DRUG
Intervention: Anti-reflux pharmacotherapy
Study NCT03618888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructor-led training
Description: The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
Study NCT03618888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-learning training
Description: The self-learning training contents a standard kit for self-directed training in BLS
Study NCT00785031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: internet based vascular risk factor intervention
Description: The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
Study NCT01466569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-7
Description: Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
Study NCT01466569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-7
Description: Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Study NCT01142063 — intervention group
Intervention type: DRUG
Intervention: Neratinib
Description: Tablet, a 240 mg single oral dose
Study NCT04207372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein isolate
Description: whey protein isolate
Study NCT04207372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zein
Description: zein protein
Study NCT04207372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: protein-free
Description: protein free
Study NCT01630668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One-a-Day L. reuteri NCIMB 30242 supplement capsule
Description: Once per day, 12 weeks
Study NCT01630668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: One-a-Day placebo capsule
Description: Once per day, 12 weeks
Study NCT03233542 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behaviour Therapy
Description: Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
Study NCT03233542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy
Description: Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
Study NCT01544907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PTA
Description: Use of conventional balloon for angioplasty only
Study NCT01544907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon (DEB)
Description: Use of DEB after conventional balloon angioplasty
Study NCT04884191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib
Study NCT03133299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Oral prednisolone for four months
Study NCT03133299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Oral prednisolone for four months
Study NCT02515955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will receive minocycline 100 mg as capsule twice daily.
Study NCT03133299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral vitamin D for two months
Study NCT03556410 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sleep
Description: Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
Study NCT03556410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep
Description: Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
Study NCT03556410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
Study NCT01849523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based information and support
Study NCT01762982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.13% Benzalkonium Chloride
Description: Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
Study NCT01762982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLS Solution
Description: Finn Chamber filled with SLS (0.3% w/v) water solution
Study NCT01762982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Water
Description: Finn Chamber filled with Normal Saline water (0.9% w/v)